ReviewFrontiers in molecular biosciences2026
Chemerin/ChemerinR1 axis and inflammation-related diseases.
Review in Frontiers in molecular biosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammation-related diseases, including cardiovascular diseases, immune disorders, and infectious diseases, have high prevalence and disability rates, imposing heavy socioeconomic and healthcare burdens. Thus, elucidating the molecular mechanisms underlying inflammation and identifying therapeutic targets are critical for the treatment of inflammation-related diseases. Chemerin, an adipokine and chemotactic protein, primarily mediates its biological effects through ChemerinR1, a G protein-coupled receptor (GPCR). Over the past 3 decades, the Chemerin/ChemerinR1 axis has been implicated in the regulation of various physiological processes, such as inflammation, metabolism, and immune response. We have comprehensively reviewed this axis plays an important role in the onset, progression, and prognosis of inflammation-related diseases, highlighting its translational potential for understanding these diseases and developing targeted therapies. This review aims to elucidate the specific mechanism of the Chemerin/ChemerinR1 axis in inflammation-related diseases. Specifically, the Chemerin/ChemerinR1 axis activates the mitogen-activated protein kinase (MAPK), PI3K/Akt, and NF-κB signaling pathways, thereby further regulating cell functions and the initiation and progression of inflammation. We also elucidate the effect of the Chemerin/ChemerinR1 axis on various inflammation-related diseases, such as hypertension, atherosclerosis, stroke, obesity, rheumatoid arthritis, and inflammatory bowel disease. Additionally, the Chemerin/ChemerinR1 axis can serve as a biomarker for various inflammation-related diseases, enabling early diagnosis, disease monitoring, and evaluation of treatment effects. Therefore, targeting the Chemerin/ChemerinR1 axis holds great potential for the treatment of vascular inflammatory diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.